NR3C2 and atrial fibrillation: Mineralocorticoid receptor antagonists such as spironolactone and eplerenone have been found to exert antifibrotic and anti-inflammatory effects on the atrial myocardium, potentially reducing the structural remodeling that predisposes to atrial fibrillation.